Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Transplantation
  Free Subscription

Articles published in
J Hepatol
    November 2026
  1. YI X, Meng C, Zhang H, Lu Q, et al
    Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration.
    J Hepatol. 2026;85:930-945.
    >> Share

    October 2026
  2. MAZZAFERRO V, Pinter M, Pillai A, Sposito C, et al
    Liver transplantation for primary liver cancers in the era of transplant oncology.
    J Hepatol. 2026;85:727-739.
    >> Share

    September 2026
  3. GUSTOT T, Bernal W, Fernandez J, Uson-Raposo E, et al
    Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study.
    J Hepatol. 2026 Sep 30:S0168-8278(26)02908-9. doi: 10.1016/j.jhep.2026.
    >> Share

  4. LIU Y, Wang B, Sun D, Zhou A, et al
    EBV-reactive KIR+ CX3CR1+ CD8+ T cells mediate liver transplantation tolerance.
    J Hepatol. 2026 Sep 23:S0168-8278(26)02897-7. doi: 10.1016/j.jhep.2026.
    >> Share

  5. CHEN R, Li X, Zhu P, Yi X, et al
    CD34(+) cell-derived endothelial cells orchestrate vascular and immune remodeling in the transplanted liver.
    J Hepatol. 2026;85:537-550.
    >> Share

    July 2026
  6. GUO Z, Zhao Q, Jia Z, Huang C, et al
    Corrigendum to: "A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease" [J Hepatol 79 (2023) 394-402].
    J Hepatol. 2026 Jul 30:S0168-8278(26)02711-X. doi: 10.1016/j.jhep.2026.
    >> Share

  7. BHOORI S, Rivoltini L, Leoncini G, Sioli V, et al
    Revisiting rejection after immune checkpoint inhibitor exposure prior to liver transplantation for hepatocellular carcinoma: Reply to: "Rejection and perioperative management in liver transplantation following immune checkpoint inhibitor-based downsta
    J Hepatol. 2026 Jul 30:S0168-8278(26)02749-2. doi: 10.1016/j.jhep.2026.
    >> Share

  8. LING Q, Xie H, Lu D, Wei X, et al
    Retraction notice to "Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population" [J Hepatol 58 (2013) 271-277].
    J Hepatol. 2026 Jul 7:S0168-8278(26)02626-7. doi: 10.1016/j.jhep.2026.
    >> Share

    June 2026
  9. YU S, Yu J, Zhang W, Cheng L, et al
    Retraction notice to "Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation" [J Hepatol 61 (2014) 809-815].
    J Hepatol. 2026 Jun 12:S0168-8278(26)02588-2. doi: 10.1016/j.jhep.2026.
    >> Share

  10. LOUVET A, Ntandja Wandji LC, Mathurin P
    Updates in clinical science: Alcohol-related hepatitis.
    J Hepatol. 2026 Jun 10:S0168-8278(26)00219-9. doi: 10.1016/j.jhep.2026.
    >> Share

    May 2026
  11. WANG P, Li H, Chen Y, Zhong L, et al
    Rejection and perioperative management in liver transplantation following immune checkpoint inhibitor-based downstaging for hepatocellular carcinoma.
    J Hepatol. 2026 May 2:S0168-8278(26)00224-2. doi: 10.1016/j.jhep.2026.
    >> Share

  12. MURPHY N, El-Dalil P, Patel S, Ryan J, et al
    Use of intracranial pressure monitoring and risk factors for the development of intracranial hypertension in acute liver failure.
    J Hepatol. 2026;84:898-905.
    >> Share

    April 2026
  13. BRAADLAND PR, Ali AH, Puchas P, Juran BD, et al
    Vitamin B6 predicts poor outcomes in geographically distinct populations with primary sclerosing cholangitis.
    J Hepatol. 2026 Apr 17:S0168-8278(26)00203-5. doi: 10.1016/j.jhep.2026.
    >> Share

    March 2026
  14. ZHANG W, Xu Q, Xu K, Jiang R, et al
    Genetically engineered pig-to-human liver xenotransplantation.
    J Hepatol. 2026;84:587-598.
    >> Share

    February 2026
  15. BHOORI S, Rivoltini L, Pinato DJ, Bellia V, et al
    Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL).
    J Hepatol. 2026 Feb 26:S0168-8278(26)00084-X. doi: 10.1016/j.jhep.2026.
    >> Share

  16. JULIEBO AT, Folseraas T, Karlsen TH, Boberg KM, et al
    Differences in Immunosuppressive Strategies for Primary Sclerosing Cholangitis After Liver Transplantation.
    J Hepatol. 2026 Feb 19:S0168-8278(26)00073-5. doi: 10.1016/j.jhep.2026.
    >> Share

  17. CHAN LL, Sun Wong VW, Chan SL
    Letter: Recurrence pattern for HBV-related HCC after liver transplantation in the antiviral era. Authors' reply.
    J Hepatol. 2026 Feb 11:S0168-8278(26)00066-8. doi: 10.1016/j.jhep.2026.
    >> Share

  18. ZHANG C, Wang R, Wang Z
    The 2025 BCLC Staging System: Should Potential Liver Transplantation Be Prioritized?
    J Hepatol. 2026 Feb 2:S0168-8278(26)00060-7. doi: 10.1016/j.jhep.2026.
    >> Share

  19. PARENTE A, Verhoeff K, Ray S, Selzner M, et al
    Utilization of liver grafts obtained from donation after medical assistance in dying: A Canadian multicenter experience.
    J Hepatol. 2026;84:329-338.
    >> Share

    January 2026
  20. KIM NG, Yao FY, Kwong AJ, Mehta N, et al
    Yttrium-90 radioembolization is associated with a lower risk of liver transplant waitlist dropout than chemoembolization in hepatocellular carcinoma.
    J Hepatol. 2026 Jan 22:S0168-8278(26)00020-6. doi: 10.1016/j.jhep.2026.
    >> Share

    December 2025
  21. LI H, Zhao R, Zheng S, Xu X, et al
    Recurrence pattern for HBV-related HCC after liver transplantation in the antiviral era.
    J Hepatol. 2025 Dec 10:S0168-8278(25)02716-3. doi: 10.1016/j.jhep.2025.
    >> Share

    October 2025
  22. LAMARQUE C, Segaux L, Bachellier P, Buchard B, et al
    Corrigendum to: "Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study" [J Hepatol (2024) 278-288].
    J Hepatol. 2025 Oct 27:S0168-8278(25)02553-X. doi: 10.1016/j.jhep.2025.
    >> Share

  23. WEDEMEYER H, Tacke F, Newsome P, Ratziu V, et al
    The first human xenogeneic liver transplantation - A landmark event, but what does it mean for hepatology?
    J Hepatol. 2025 Oct 9:S0168-8278(25)02496-1. doi: 10.1016/j.jhep.2025.
    >> Share

  24. WONG YJ, Lam L, Soret PA, Lemoinne S, et al
    Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.
    J Hepatol. 2025 Oct 3:S0168-8278(25)02519-X. doi: 10.1016/j.jhep.2025.
    >> Share

  25. YANG P, Wang X, Wu W, Yuan J, et al
    Decoding the resistin-CAP1 pathway in intermediate monocytes mediating liver allograft rejection.
    J Hepatol. 2025;83:931-945.
    >> Share

  26. RUSSO FP, Murad SD, Pillai AA, Shingina A, et al
    Combined liver with other solid organ transplants: Promises, pitfalls and ethical dilemmas.
    J Hepatol. 2025;83:982-988.
    >> Share

    September 2025
  27. WEHRLE CJ, Fujiki M, Uso TD, Hashimoto K, et al
    Portal Venous Flow in Pediatric Liver Transplantation.
    J Hepatol. 2025 Sep 2:S0168-8278(25)02467-5. doi: 10.1016/j.jhep.2025.
    >> Share

    August 2025
  28. VAZ J, Hagstrom H
    Phosphatidylethanol for monitoring alcohol use after liver transplantation.
    J Hepatol. 2025 Aug 30:S0168-8278(25)02461-4. doi: 10.1016/j.jhep.2025.
    >> Share

  29. ROSSIGNOL G, Muller X, Dubois R, Mohkam K, et al
    Hemodynamic Graft-Recipient Matching in Pediatric Liver Transplantation: Just Graft with the Flow.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02448-1. doi: 10.1016/j.jhep.2025.
    >> Share

    July 2025
  30. ENGEL B, Alaswad A, Campos-Murguia A, Zoodsma M, et al
    Molecular signatures discriminating different types of rejection in human liver transplants.
    J Hepatol. 2025 Jul 14:S0168-8278(25)02338-4. doi: 10.1016/j.jhep.2025.
    >> Share

  31. WEHRLE CJ, Fujiki M, Satish S, Iuppa G, et al
    Mechanisms and Management of Graft In- and Out-flow in Liver Transplantation: A Narrative Review of the Literature and Guide for Interventional Management.
    J Hepatol. 2025 Jul 4:S0168-8278(25)02324-4. doi: 10.1016/j.jhep.2025.
    >> Share

    June 2025
  32. HESSHEIMER AJ, Hartog H, Marcon F, Schlegel A, et al
    Deceased donor liver utilisation and assessment: Consensus guidelines from the European Liver and Intestine Transplant Association.
    J Hepatol. 2025;82:1089-1109.
    >> Share

    May 2025
  33. GANGADHAR A, Hasjim BJ, Zhao X, Sun Y, et al
    Personalized survival benefit estimation from living donor liver transplantation with a novel machine learning method for confounding adjustment.
    J Hepatol. 2025 May 28:S0168-8278(25)02253-6. doi: 10.1016/j.jhep.2025.
    >> Share


  34. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.
    J Hepatol. 2025 May 10:S0168-8278(25)00173-4. doi: 10.1016/j.jhep.2025.
    >> Share

    April 2025
  35. MOORE LW, Brombosz EW, Ghobrial RM
    To Sleeve or Not to Sleeve: Validation of Liver Transplantation with Sleeve Gastrectomy.
    J Hepatol. 2025 Apr 15:S0168-8278(25)00242-9. doi: 10.1016/j.jhep.2025.
    >> Share

  36. BURKE L, Bernal W, Pirani T, Agarwal B, et al
    Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort.
    J Hepatol. 2025;82:615-621.
    >> Share

    March 2025
  37. HUWYLER F, Pfister M, Binz J, Tibbitt MW, et al
    Benefits of multi-day ex situ perfusion include dampened ischemia reperfusion injury in liver transplantation.
    J Hepatol. 2025 Mar 25:S0168-8278(25)00208-9. doi: 10.1016/j.jhep.2025.
    >> Share

  38. LARSON EL, Ellias SD, Blezek DJ, Klug J, et al
    Simultaneous liver transplant and sleeve gastrectomy provides durable weight loss, improves metabolic syndrome and reduces allograft steatosis.
    J Hepatol. 2025 Mar 13:S0168-8278(25)00139-4. doi: 10.1016/j.jhep.2025.
    >> Share

  39. ARTRU F, Ursic-Bedoya J, L'Hermite S, Saliba F, et al
    Reply to : "Long-term outcome following liver transplantation of patients with ACLF grade 3 : Need of redefining boundaries ?".
    J Hepatol. 2025 Mar 5:S0168-8278(25)00133-3. doi: 10.1016/j.jhep.2025.
    >> Share

  40. EDEN J, Thorne AM, Bodewes SB, Patrono D, et al
    Assessment of liver graft quality during hypothermic oxygenated perfusion: The first international validation study.
    J Hepatol. 2025;82:523-534.
    >> Share

    February 2025
  41. HE K, Chen L, Xia Q
    Is MELD-Cr an Accurate Predictor of Liver Transplant Outcomes? A Call for Refinement in Allocation Criteria.
    J Hepatol. 2025 Feb 20:S0168-8278(25)00095-9. doi: 10.1016/j.jhep.2025.
    >> Share

  42. ROSENSTENGLE C, Serper M, Asrani SK, Bittermann T, et al
    Variation in intention-to-treat survival by MELD subtypes: All models created for end-stage liver disease are not equal.
    J Hepatol. 2025;82:268-276.
    >> Share

    January 2025
  43. MISHRA AK
    Long-term outcome following liver transplantation of patients with ACLF grade 3 : Need of redefining boundaries?
    J Hepatol. 2025 Jan 23:S0168-8278(25)00024-8. doi: 10.1016/j.jhep.2025.
    >> Share

  44. ACEITUNO L, Gravely AK, O'Kane GM, Vogel A, et al
    The use of immunotherapy pre-liver transplant.
    J Hepatol. 2025 Jan 3:S0168-8278(24)02702-8. doi: 10.1016/j.jhep.2024.
    >> Share

  45. REZAEE-ZAVAREH MS, Yeo YH, Wang T, Guo Z, et al
    Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.
    J Hepatol. 2025;82:107-119.
    >> Share

  46. EDEN J, Bruggenwirth IMA, Berlakovich G, Buchholz BM, et al
    Long-term outcomes after hypothermic oxygenated machine perfusion and transplantation of 1,202 donor livers in a real-world setting (HOPE-REAL study).
    J Hepatol. 2025;82:97-106.
    >> Share

    December 2024

  47. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.
    J Hepatol. 2024 Dec 16:S0168-8278(24)02508-X. doi: 10.1016/j.jhep.2024.
    >> Share

    November 2024
  48. DE GOEIJ FHC, Wehrle CJ, Abassi F, Satish S, et al
    Mastering the Narrative: Precision Reporting of Risk and Outcomes in Liver Transplantation.
    J Hepatol. 2024 Nov 16:S0168-8278(24)02713-2. doi: 10.1016/j.jhep.2024.
    >> Share

    October 2024
  49. SAMUEL D
    EASL Clinical Practice Guidelines on liver transplantation.
    J Hepatol. 2024 Oct 23:S0168-8278(24)02440-1. doi: 10.1016/j.jhep.2024.
    >> Share

  50. PARENTE A, Wehrle CJ, Schold JD, Panconesi R, et al
    Reply to: "Trends in current use of machine perfusion for donation after cardiac death donors in the US".
    J Hepatol. 2024;81:e189-e191.
    >> Share

  51. MATEVISH LE, Vagefi PA, Patel MS
    Trends in current use of machine perfusion for donation after cardiac death donors in the US.
    J Hepatol. 2024;81:e187-e188.
    >> Share

    September 2024
  52. REZAEE-ZAVAREH MS, Guo Z, Yang JD
    Addressing the Complexities of Pre-Liver Transplant Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Response to Recent Commentaries.
    J Hepatol. 2024 Sep 19:S0168-8278(24)02558-3. doi: 10.1016/j.jhep.2024.
    >> Share

  53. TABRIZIAN P, Holzner M, Ajmera V, Kim AK, et al
    Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study.
    J Hepatol. 2024 Sep 8:S0168-8278(24)02541-8. doi: 10.1016/j.jhep.2024.
    >> Share

  54. ALLEN E, Taylor R, Gimson A, Thorburn D, et al
    Transplant benefit-based offering of deceased donor livers in the United Kingdom.
    J Hepatol. 2024;81:471-478.
    >> Share

    August 2024
  55. MAGAZ M, Giudicelli-Lett H, G Abraldes J, Nicoara-Farcau O, et al
    Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome.
    J Hepatol. 2024 Aug 22:S0168-8278(24)02481-4. doi: 10.1016/j.jhep.2024.
    >> Share

  56. DE HAAN J, Termorshuizen F, de Keizer N, Gommers D, et al
    One-year transplant-free survival following hospital discharge after ICU admission for ACLF in the Netherlands.
    J Hepatol. 2024;81:238-247.
    >> Share

    July 2024
  57. VAN LEEUWEN LL, Irizar H, Kim-Schluger L, Florman S, et al
    The Potential of Machine Learning to Predict Early Allograft Dysfunction after Normothermic Machine Perfusion in Liver transplantation.
    J Hepatol. 2024 Jul 31:S0168-8278(24)02438-3. doi: 10.1016/j.jhep.2024.
    >> Share

  58. HAO L, Shan D, Xue J
    Strategic Timing and Patient Selection for ICIs Prior to Liver Transplantation for HCC.
    J Hepatol. 2024 Jul 27:S0168-8278(24)02432-2. doi: 10.1016/j.jhep.2024.
    >> Share

  59. ARTRU F, Sacleux SC, Ursic-Bedoya J, Ntandja Wandji LC, et al
    Long-term outcome following liver transplantation of patients with ACLF grade 3.
    J Hepatol. 2024 Jul 7:S0168-8278(24)02346-8. doi: 10.1016/j.jhep.2024.
    >> Share

    June 2024
  60. FUSTER-ANGLADA C, Mauro E, Ferrer-Fabrega J, Caballol B, et al
    Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection.
    J Hepatol. 2024 Jun 24:S0168-8278(24)02324-9. doi: 10.1016/j.jhep.2024.
    >> Share

  61. ESSER H, Kilpatrick AM, Man TY, Aird R, et al
    Primary cilia as a targetable node between biliary injury, senescence and regeneration in liver transplantation.
    J Hepatol. 2024 Jun 13:S0168-8278(24)02302-X. doi: 10.1016/j.jhep.2024.
    >> Share

  62. HE T, Sun K, Zou J
    Biomarker predictors and LRT strategies for HCC recurrence post-liver transplantation: A comment.
    J Hepatol. 2024 Jun 6:S0168-8278(24)00422-7. doi: 10.1016/j.jhep.2024.
    >> Share

  63. LI M, Bhoori S, Mehta N, Mazzaferro V, et al
    Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.
    J Hepatol. 2024 Jun 5:S0168-8278(24)00423-9. doi: 10.1016/j.jhep.2024.
    >> Share

  64. NORMAN JS, Mehta N
    Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
    J Hepatol. 2024;80:e273-e274.
    >> Share

    May 2024
  65. CHICHELNITSKIY E, Goldschmidt I, Ruhl L, Rubsamen N, et al
    Plasma immune signatures can predict rejection-free survival in the first year after pediatric liver transplantation.
    J Hepatol. 2024 May 29:S0168-8278(24)00367-2. doi: 10.1016/j.jhep.2024.
    >> Share

  66. MONTANO-LOZA AJ, Lytvyak E, Hirschfield G, Hansen BE, et al
    Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation.
    J Hepatol. 2024 May 29:S0168-8278(24)00345-3. doi: 10.1016/j.jhep.2024.
    >> Share

  67. SPADA M, Angelico R, Trapani S, Masiero L, et al
    Reply to: "Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding".
    J Hepatol. 2024 May 15:S0168-8278(24)00346-5. doi: 10.1016/j.jhep.2024.
    >> Share

  68. GAMBELLA A, Salvi M, Molinari F
    Response to: Application of Digital Pathology in Liver Transplantation.
    J Hepatol. 2024 May 15:S0168-8278(24)00350-7. doi: 10.1016/j.jhep.2024.
    >> Share

  69. MULLER X, Rossignol G, Boulanger N, Mohkam K, et al
    In situ or ex situ split: Does it all come down to static cold storage?
    J Hepatol. 2024;80:e210-e211.
    >> Share

    March 2024
  70. LI Y, Yang F, Liu K
    Application of Digital Pathology in Liver Transplantation.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00207-1. doi: 10.1016/j.jhep.2024.
    >> Share

  71. LAMARQUE C, Segaux L, Bachellier P, Buchard B, et al
    Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study.
    J Hepatol. 2024 Mar 21:S0168-8278(24)00202-2. doi: 10.1016/j.jhep.2024.
    >> Share

  72. GAMBELLA A, Salvi M, Molinaro L, Patrono D, et al
    Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms.
    J Hepatol. 2024;80:495-504.
    >> Share

    February 2024
  73. MARTIN-MATEOS R, Martinez-Arenas L, Carvalho-Gomes A, Aceituno L, et al
    Multidrug-resistant bacterial infections after liver transplantation: prevalence, impact, and risk factors.
    J Hepatol. 2024 Feb 28:S0168-8278(24)00128-4. doi: 10.1016/j.jhep.2024.
    >> Share

  74. DE VILLE DE GOYET J
    Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding: Comment on:Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period. Spada M,
    J Hepatol. 2024 Feb 12:S0168-8278(24)00126-0. doi: 10.1016/j.jhep.2024.
    >> Share

  75. SOIN A, Lesurtel M, Clavien PA
    To the editor: Reply to the letter by Liu et al. entitled "Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis".
    J Hepatol. 2024 Feb 8:S0168-8278(24)00101-6. doi: 10.1016/j.jhep.2024.
    >> Share

    January 2024
  76. LAUTERIO A, Cillo U, De Carlis R, Bernasconi D, et al
    Reply to: "Outcome of in-situ split liver transplantation in Italy over the last 25 years: an alternative analysis and personal view".
    J Hepatol. 2024 Jan 25:S0168-8278(24)00057-6. doi: 10.1016/j.jhep.2024.
    >> Share

  77. TABRIZIAN P, Abdelrahim M, Schwartz M
    Immunotherapy and Transplantation for Hepatocellular Carcinoma.
    J Hepatol. 2024 Jan 20:S0168-8278(24)00053-9. doi: 10.1016/j.jhep.2024.
    >> Share

    December 2023
  78. NORMAN JS, Mehta N
    Reply to: Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Dec 26:S0168-8278(23)05371-0. doi: 10.1016/j.jhep.2023.
    >> Share

  79. SPADA M, Angelico R, Trapani S, Masiero L, et al
    Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period.
    J Hepatol. 2023 Dec 18:S0168-8278(23)05308-4. doi: 10.1016/j.jhep.2023.
    >> Share

  80. SMEETS JJH, van Malenstein H, van der Merwe S, Nevens F, et al
    SARS-CoV-2 anti-spike IgG antibodies are present in all liver transplant recipients after fifth vaccine dose.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05362-X. doi: 10.1016/j.jhep.2023.
    >> Share

  81. PARENTE A, Jiao C, Eden J, Dutkowski P, et al
    machine perfusion, randomized controlled trials, liver transplantation, immune cellsPerfusate immune cell profiling during machine perfusion - A new tool to link risk and immune response after liver transplantation?
    J Hepatol. 2023 Dec 16:S0168-8278(23)05364-3. doi: 10.1016/j.jhep.2023.
    >> Share

  82. HAHN M, Herber A, Berg T, Seehofer D, et al
    Enhancing HCC Recurrence Prediction after Liver Transplantation: from DCP plus AFP-L3 model to GALAD Score.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05357-6. doi: 10.1016/j.jhep.2023.
    >> Share

  83. DE CARLIS R, Lauterio A, Bernasconi D, Taner B, et al
    Reply to: "Excellent long-term outcomes after sequential hypothermic and normothermic machine perfusion challenges the importance of functional donor warm ischemia time in DCD liver transplantation": Further comments on the changing role of donor warm
    J Hepatol. 2023;79:e245-e247.
    >> Share

    November 2023
  84. PARENTE A, Dondossola D, Dutkowski P, Schlegel A, et al
    Current evidence on the beneficial HOPE-effect based on systematic reviews and meta-analyses in liver transplantation.
    J Hepatol. 2023 Nov 10:S0168-8278(23)05233-9. doi: 10.1016/j.jhep.2023.
    >> Share

  85. LIU J, Qian J, Yang Z, Zhou L, et al
    Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation:A meta-analysis.
    J Hepatol. 2023 Nov 6:S0168-8278(23)05231-5. doi: 10.1016/j.jhep.2023.
    >> Share

    October 2023
  86. MURRAY SM, Pose E, Wittner M, Londono MC, et al
    Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients.
    J Hepatol. 2023 Oct 18:S0168-8278(23)05174-7. doi: 10.1016/j.jhep.2023.
    >> Share

  87. DE VILLE DE GOYET J
    Outcome of in-situ split liver transplantation in Italy over the last 25 years : an alternative analysis and personal view.
    J Hepatol. 2023 Oct 12:S0168-8278(23)05151-6. doi: 10.1016/j.jhep.2023.
    >> Share

  88. SHA M, Cao J, Xia Q
    Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Oct 9:S0168-8278(23)05162-0. doi: 10.1016/j.jhep.2023.
    >> Share

    September 2023
  89. ABERG F, Sallinen V, Tuominen S, Adam R, et al
    Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity-score matched intention-to-treat analysis.
    J Hepatol. 2023 Sep 16:S0168-8278(23)05100-0. doi: 10.1016/j.jhep.2023.
    >> Share

  90. CHOUDHARY NS, Dhampalwar S, Saraf N, Soin AS, et al
    Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
    J Hepatol. 2023 Sep 15:S0168-8278(23)05098-5. doi: 10.1016/j.jhep.2023.
    >> Share

  91. NORMAN JS, Li PJ, Kotwani P, Shui AM, et al
    AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    J Hepatol. 2023 Sep 6:S0168-8278(23)05074-2. doi: 10.1016/j.jhep.2023.
    >> Share

  92. HERNAEZ R, Karvellas CJ, Liu Y, Sacleux SC, et al
    The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure.
    J Hepatol. 2023;79:717-727.
    >> Share

  93. EDEN J, Dutkowski P, Schlegel A
    Reply to: "How many liver grafts could be recovered after implementation of donation after cardiac death in Germany?".
    J Hepatol. 2023;79:e120-e121.
    >> Share

  94. EDEN J, von Felten S, Dutkowski P, Schlegel A, et al
    Reply to: "A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation".
    J Hepatol. 2023;79:e116-e118.
    >> Share

  95. SHARMA N, Pandey S, Yadav M, Mathew B, et al
    Biomolecular map of albumin identifies signatures of severity and early mortality in acute liver failure.
    J Hepatol. 2023;79:677-691.
    >> Share

  96. HAKEEM AR, Taylor R, Prasad R
    Comment on "Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicentre analysis of the US, the UK, and Canada".
    J Hepatol. 2023;79:e112-e114.
    >> Share

  97. CZIGANY Z, Michalski CW
    A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation.
    J Hepatol. 2023;79:e114-e116.
    >> Share

    August 2023
  98. TANG G, Zhang L, Zhou R
    Letter to the Editor: Machine perfusion techniques for liver transplantation - A meta-analysis of the first seven randomized controlled trials.
    J Hepatol. 2023 Aug 8:S0168-8278(23)05045-6. doi: 10.1016/j.jhep.2023.
    >> Share


  99. EASL Clinical Practice Guidelines on acute-on-chronic liver failure.
    J Hepatol. 2023;79:461-491.
    >> Share

  100. KARTOUN U
    Fairness metrics: Additional principles to consider for improving MELD.
    J Hepatol. 2023;79:e80-e81.
    >> Share

    July 2023
  101. VAN LEEUWEN OB, Bodewes SB, Porte RJ, de Meijer VE, et al
    Excellent long-term outcome after sequential hypothermic and normothermic machine perfusion challenges the importance of functional donor warm ischemia time in DCD liver transplantation.
    J Hepatol. 2023 Jul 27:S0168-8278(23)05004-3. doi: 10.1016/j.jhep.2023.
    >> Share

  102. LAUTERIO A, Cillo U, Spada M, Trapani S, et al
    Improving outcomes of in situ split liver transplantation in Italy over the last 25 years.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04988-7. doi: 10.1016/j.jhep.2023.
    >> Share

    June 2023
  103. BRAADLAND PR, Bergquist A, Kummen M, Bossen L, et al
    Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.
    J Hepatol. 2023 Jun 14:S0168-8278(23)00415-4. doi: 10.1016/j.jhep.2023.
    >> Share

  104. LIM WH, Ng CH, Hao Tan DJ, Tseng M, et al
    Natural history of NASH cirrhosis in liver transplant waitlist registrants.
    J Hepatol. 2023 Jun 10:S0168-8278(23)00412-9. doi: 10.1016/j.jhep.2023.
    >> Share

  105. PARENTE A, Tirotta F, Pini A, Eden J, et al
    Machine perfusion techniques for liver transplantation - A meta-analysis of the first seven randomized controlled trials.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00399-9. doi: 10.1016/j.jhep.2023.
    >> Share

  106. KAPLAN A, Korenjak M, Brown RS Jr
    Post-liver transplantation patient experience.
    J Hepatol. 2023;78:1234-1244.
    >> Share

  107. BHAT M, Rabindranath M, Chara BS, Simonetto DA, et al
    Artificial intelligence, machine learning, and deep learning in liver transplantation.
    J Hepatol. 2023;78:1216-1233.
    >> Share

  108. MONTANO-LOZA AJ, Rodriguez-Peralvarez ML, Pageaux GP, Sanchez-Fueyo A, et al
    Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation.
    J Hepatol. 2023;78:1199-1215.
    >> Share

  109. DE CARLIS R, Paolo Muiesan, Taner B
    Donation after circulatory death: Novel strategies to improve the liver transplant outcome.
    J Hepatol. 2023;78:1169-1180.
    >> Share

  110. GERMANI G, Mathurin P, Lucey MR, Trotter J, et al
    Early liver transplantation for severe acute alcohol-related hepatitis after more than a decade of experience.
    J Hepatol. 2023;78:1130-1136.
    >> Share

  111. SOIN A, Lesurtel M, Bhangui P, Cocchi L, et al
    Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?
    J Hepatol. 2023;78:1124-1129.
    >> Share

  112. ARTRU F, Goldberg D, Kamath PS
    Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation?
    J Hepatol. 2023;78:1118-1123.
    >> Share

  113. TANDON P, Zanetto A, Piano S, Heimbach JK, et al
    Liver transplantation in the patient with physical frailty.
    J Hepatol. 2023;78:1105-1117.
    >> Share

  114. BURRA P
    The changing world of liver transplantation.
    J Hepatol. 2023;78:1087-1088.
    >> Share

  115. SCHLEGEL A, Mergental H, Fondevila C, Porte RJ, et al
    Machine perfusion of the liver and bioengineering.
    J Hepatol. 2023;78:1181-1198.
    >> Share

  116. TANER T, Hilscher MB, Broda CR, Drenth JPH, et al
    Issues in multi-organ transplantation of the liver with kidney or heart in polycystic liver-kidney disease or congenital heart disease: Current practices and immunological aspects.
    J Hepatol. 2023;78:1157-1168.
    >> Share

  117. KASAHARA M, Hong JC, Dhawan A
    Evaluation of living donors for hereditary liver disease (siblings, heterozygotes).
    J Hepatol. 2023;78:1147-1156.
    >> Share

    May 2023
  118. EDEN J, Sousa Da Silva R, Cortes-Cerisuelo M, Croome K, et al
    Utilization of livers donated after circulatory death for transplantation - An international comparison.
    J Hepatol. 2023;78:1007-1016.
    >> Share

    April 2023
  119. GUO Z, Zhao Q, Jia Z, Huang C, et al
    A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease.
    J Hepatol. 2023 Apr 20:S0168-8278(23)00233-7. doi: 10.1016/j.jhep.2023.
    >> Share

  120. SCHLEGEL A, Mueller M, Muller X, Eden J, et al
    A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation.
    J Hepatol. 2023;78:783-793.
    >> Share

    March 2023
  121. MOOSBURNER S, Sauer IM, Weiss B, Pratschke J, et al
    How many liver transplantations could be recovered after implementation of donation after cardiac death in Germany?
    J Hepatol. 2023 Mar 11:S0168-8278(23)00176-9. doi: 10.1016/j.jhep.2023.
    >> Share

  122. GE J, Kim WR, Lai JC, Kwong AJ, et al
    Response to: "Towards optimally replacing the current version of MELD".
    J Hepatol. 2023;78:e100-e101.
    >> Share

  123. KARTOUN U
    Towards optimally replacing the current version of MELD.
    J Hepatol. 2023;78:e98-e99.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016